Raja Dashti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raja Dashti has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Mohammed Al Jarallah
Department of Cardiology, Sabah Al Ahmed Cardiac Centre, Al Amiri Hospital, Kuwait City, Kuwait
11 shared publications - Rajesh Rajan
Department of Cardiology, Sabah Al Ahmad Cardiac Center, Al Amiri Hospital, Sharq, Kuwait
11 shared publications - Ibrahim Al-Zakwani
Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
4 shared publications Khalid Al Mulla
Department of Cardiology, Sabah Al Ahmed Cardiac Centre, Al Amiri Hospital, Kuwait City, Kuwait
4 shared publications- Ahmad Alsaber
Department of Management, American University of Kuwait, Salmiya, Kuwait
3 shared publications Gary Tse
Department of Cardiology, Cardiovascular Analytics Group, London, UK
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 8 (1) , 18-29
Aortic Regurgitation Quantification, Management, and Guidelines: A 2026 Update
We sought to compare recommendations from the European Society of Cardiology and the American College of Cardiology/American Heart Association guidelines, for the diagnosis and management of aortic regurgitation (AR), a major cause of valvular heart disease. Both guidelines agreed on a multidisciplinary approach to grade the mechanism and severity of AR. In both guidelines, surgical aortic valve (AV) replacement remains the predominant treatment modality after the surgical risk profile has been determined. Trans-catheter AV implantation is an alternative, but further data are needed to determine its efficacy. This review article focuses on AR and describes the prevalence, mechanisms, diagnosis, and treatment of AR.
- 1 January 2026
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 8 (1) , 18-29
Open AccessAortic Regurgitation Quantification, Management, and Guidelines: A 2026 Update
We sought to compare recommendations from the European Society of Cardiology and the American College of Cardiology/American Heart Association guidelines, for the diagnosis and management of aortic regurgitation (AR), a major cause of valvular heart disease. Both guidelines agreed on a multidisciplinary approach to grade the mechanism and severity of AR. In both guidelines, surgical aortic valve (AV) replacement remains the predominant treatment modality after the surgical risk profile has been determined. Trans-catheter AV implantation is an alternative, but further data are needed to determine its efficacy. This review article focuses on AR and describes the prevalence, mechanisms, diagnosis, and treatment of AR.
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 7 (2) , 64-79
A 2025 Update on Mitral Valve Disease – Focusing on Mitral Stenosis: Quantification, Clinical Management, and Guideline Review
A comparison of the recommendations for the diagnosis and management of mitral stenosis (MS), the major cause of valvular heart disease globally, from the European Society of Cardiology/European Association to the American College of Cardiology/American Heart Association 2020 guidelines. We systematically reviewed and contrasted the guidelines on the diagnosis and management of MS to appraise clinical judgment. A multimodel approach includes transesophageal echocardiogram (TEE), transthoracic echocardiogram (TTE), cardiac catheterization, exercise testing, and transcatheter mitral valve repair or replacement/transcatheter mitral valve implantation. Both guidelines agreed on medical therapy, which is anticoagulation, which has been shown to reduce the thromboembolic events in rheumatic MS. On the other hand, there was a subtle difference between both guidelines in staging the severity of MS. In addition, there was a disagreement regarding whether to perform a regular follow-up or to perform surgery.
- 1 July 2025
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 7 (2) , 64-79
Open AccessA 2025 Update on Mitral Valve Disease – Focusing on Mitral Stenosis: Quantification, Clinical Management, and Guideline Review
A comparison of the recommendations for the diagnosis and management of mitral stenosis (MS), the major cause of valvular heart disease globally, from the European Society of Cardiology/European Association to the American College of Cardiology/American Heart Association 2020 guidelines. We systematically reviewed and contrasted the guidelines on the diagnosis and management of MS to appraise clinical judgment. A multimodel approach includes transesophageal echocardiogram (TEE), transthoracic echocardiogram (TTE), cardiac catheterization, exercise testing, and transcatheter mitral valve repair or replacement/transcatheter mitral valve implantation. Both guidelines agreed on medical therapy, which is anticoagulation, which has been shown to reduce the thromboembolic events in rheumatic MS. On the other hand, there was a subtle difference between both guidelines in staging the severity of MS. In addition, there was a disagreement regarding whether to perform a regular follow-up or to perform surgery.
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 7 (1) , 15-26
Impact of Proprotein Convertase Subtilisin/Kexin-9 Inhibitors on Low-density Lipoprotein Cholesterol and Nonhigh-density Lipoprotein Cholesterol Stratified by Sex: A Real-world Analysis in a Kuwaiti Population
Background: Sex differences influence the response of low-density lipoprotein cholesterol (LDL-C) and nonhigh-density lipoprotein cholesterol (non-HDL-C) to lipid-lowering agents (LLAs). However, the effect of sex on newer medications such as proprotein convertase subtilisin/kexin-9 inhibitors (PCSK9Is) remains unclear, complicating sex-specific therapies for LDL-C and non-HDL-C targets. Objective: This study aimed to evaluate the clinical characteristics of Kuwaiti patients on LLAs and their LDL-C and non-HDL-C response to maximum tolerated doses of LLAs and PCSK9Is over 6 months, stratified by sex. Methods: Data were collected from patients at the Sabah Al-Ahmad Cardiac Center’s outpatient clinic from January 2021 to December 2023. Adults (≥18 years) on LLAs for over 3 months who provided consent were included in the study. Patients on the maximum tolerated doses of LLAs and those on PCSK9Is were stratified into males and females, and their total cholesterol, non-HDL-C, and LDL-C levels were assessed at baseline and at the 6-month follow-up. Results: Of 116 patients (48.3% male; mean age 50.5 ± 12.8 years), LDL-C and non-HDL-C levels were similar between sexes at baseline. After 6 months, LLAs showed a median LDL-C reduction of 26% ( P < 0.001). Men achieved better LDL-C levels (1.5 vs. 2.6 mmol/L, P < 0.001) and reached more treatment targets than women. PCSK9Is (alirocumab and evolocumab) significantly reduced LDL-C and non-HDL-C, with stronger responses in men (LDL-C: 1.3 vs. 2.5 mmol/L, P < 0.001; non-HDL-C: 2.2 vs. 3.4 mmol/L, P < 0.001). Conclusion: LLAs and PCSK9Is effectively lower LDL-C and non-HDL-C, but men show better outcomes, suggesting the need for sex-specific treatment strategies.
- 1 January 2025
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 7 (1) , 15-26
Open AccessImpact of Proprotein Convertase Subtilisin/Kexin-9 Inhibitors on Low-density Lipoprotein Cholesterol and Nonhigh-density Lipoprotein Cholesterol Stratified by Sex: A Real-world Analysis in a Kuwaiti Population
Background: Sex differences influence the response of low-density lipoprotein cholesterol (LDL-C) and nonhigh-density lipoprotein cholesterol (non-HDL-C) to lipid-lowering agents (LLAs). However, the effect of sex on newer medications such as proprotein convertase subtilisin/kexin-9 inhibitors (PCSK9Is) remains unclear, complicating sex-specific therapies for LDL-C and non-HDL-C targets. Objective: This study aimed to evaluate the clinical characteristics of Kuwaiti patients on LLAs and their LDL-C and non-HDL-C response to maximum tolerated doses of LLAs and PCSK9Is over 6 months, stratified by sex. Methods: Data were collected from patients at the Sabah Al-Ahmad Cardiac Center’s outpatient clinic from January 2021 to December 2023. Adults (≥18 years) on LLAs for over 3 months who provided consent were included in the study. Patients on the maximum tolerated doses of LLAs and those on PCSK9Is were stratified into males and females, and their total cholesterol, non-HDL-C, and LDL-C levels were assessed at baseline and at the 6-month follow-up. Results: Of 116 patients (48.3% male; mean age 50.5 ± 12.8 years), LDL-C and non-HDL-C levels were similar between sexes at baseline. After 6 months, LLAs showed a median LDL-C reduction of 26% ( P < 0.001). Men achieved better LDL-C levels (1.5 vs. 2.6 mmol/L, P < 0.001) and reached more treatment targets than women. PCSK9Is (alirocumab and evolocumab) significantly reduced LDL-C and non-HDL-C, with stronger responses in men (LDL-C: 1.3 vs. 2.5 mmol/L, P < 0.001; non-HDL-C: 2.2 vs. 3.4 mmol/L, P < 0.001). Conclusion: LLAs and PCSK9Is effectively lower LDL-C and non-HDL-C, but men show better outcomes, suggesting the need for sex-specific treatment strategies.
- Open Access
- 1 July 2024
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 6 (2) , 95-98
Atypical Presentation of Danon Disease
Danon disease (DD) is a rare X-linked disorder secondary to lysosomal-associated membrane protein 2 (LAMP2) deficiency that manifests as hypertrophic or dilated cardiomyopathy. We report an obscure presentation of DD in a 14-year-old female patient diagnosed using cardiac imaging including echocardiography and cardiac magnetic resonance imaging. A final diagnosis of DD was made after identification of LAMP2 genetic variant. The diagnosis of DD requires a high index of suspicion, particularly in female patients with atypical phenotypes. This case highlights the necessity of a holistic approach for early detection.
- 1 July 2024
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 6 (2) , 95-98
Open AccessAtypical Presentation of Danon Disease
Danon disease (DD) is a rare X-linked disorder secondary to lysosomal-associated membrane protein 2 (LAMP2) deficiency that manifests as hypertrophic or dilated cardiomyopathy. We report an obscure presentation of DD in a 14-year-old female patient diagnosed using cardiac imaging including echocardiography and cardiac magnetic resonance imaging. A final diagnosis of DD was made after identification of LAMP2 genetic variant. The diagnosis of DD requires a high index of suspicion, particularly in female patients with atypical phenotypes. This case highlights the necessity of a holistic approach for early detection.
- Open Access
- 1 January 2024
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 6 (1) , 23-35
Mortality and Morbidity in Acute Heart Failure with Cerebrovascular Accident (Stroke/Transient Ischemic Attack) Stratified by Ejection Fraction
Background: Heart failure (HF) is a prevalent condition in our society, frequently accompanied by various interacting comorbidities. Among these, brain-related comorbidities such as stroke and transient ischemic attack (TIA) play a crucial role in exacerbating the severity of HF. The relationship between cerebrovascular accidents (CVAs) and HF across different left ventricular ejection fraction (LVEF) levels is not well understood. Objectives: This study aims to assess the impact of CVA including stroke and TIA on mortality and morbidity in patients with acute heart failure (AHF) stratified by LVEF. Methods: We conducted an analysis of consecutive patients admitted to 47 hospitals in seven Middle Eastern countries (Saudi Arabia, Oman, Yemen, Kuwait, United Arab Emirates, Qatar, and Bahrain) with AHF from February to November 2012 with AHF who were enrolled in a multinational registry of patients with HF. The study population consisted of patients with CVA and AHF, categorized into three groups based on EF: HF patients with preserved EF (HFpEF) (250%), HF patients with reduced EF (HFrEF) (n = 31). Patients in different ranges of LVEF experienced comparable rates of hospitalization and mortality at both the 3-month and 12-month intervals. Left atrial enlargement (odd ratio [OR]: 3.27, 95% confidence interval [CI]: 1.33–9.32, P = 0.015) and noninvasive ventilation (OR: 6.17, 95% CI: 2.71–14.07, P < 0.001) were associated with a higher mortality rate while discharging on digoxin (OR: 0.14, 95% CI: 0.02–0.52, P = 0.011) was linked to lower mortality. The sole distinction among HF groups was observed in 12-month survival, with HFpEF patients having a superior survival rate of 91.7% compared to HFIEF patients at 77.5% and HFmrEF at 77.8% during this period. Conclusions: This study found significant differences in all-cause mortality at 12 months. Further research is warranted to better understand the mechanisms underlying these associations.
- 1 January 2024
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 6 (1) , 23-35
Open AccessMortality and Morbidity in Acute Heart Failure with Cerebrovascular Accident (Stroke/Transient Ischemic Attack) Stratified by Ejection Fraction
Background: Heart failure (HF) is a prevalent condition in our society, frequently accompanied by various interacting comorbidities. Among these, brain-related comorbidities such as stroke and transient ischemic attack (TIA) play a crucial role in exacerbating the severity of HF. The relationship between cerebrovascular accidents (CVAs) and HF across different left ventricular ejection fraction (LVEF) levels is not well understood. Objectives: This study aims to assess the impact of CVA including stroke and TIA on mortality and morbidity in patients with acute heart failure (AHF) stratified by LVEF. Methods: We conducted an analysis of consecutive patients admitted to 47 hospitals in seven Middle Eastern countries (Saudi Arabia, Oman, Yemen, Kuwait, United Arab Emirates, Qatar, and Bahrain) with AHF from February to November 2012 with AHF who were enrolled in a multinational registry of patients with HF. The study population consisted of patients with CVA and AHF, categorized into three groups based on EF: HF patients with preserved EF (HFpEF) (250%), HF patients with reduced EF (HFrEF) (n = 31). Patients in different ranges of LVEF experienced comparable rates of hospitalization and mortality at both the 3-month and 12-month intervals. Left atrial enlargement (odd ratio [OR]: 3.27, 95% confidence interval [CI]: 1.33–9.32, P = 0.015) and noninvasive ventilation (OR: 6.17, 95% CI: 2.71–14.07, P < 0.001) were associated with a higher mortality rate while discharging on digoxin (OR: 0.14, 95% CI: 0.02–0.52, P = 0.011) was linked to lower mortality. The sole distinction among HF groups was observed in 12-month survival, with HFpEF patients having a superior survival rate of 91.7% compared to HFIEF patients at 77.5% and HFmrEF at 77.8% during this period. Conclusions: This study found significant differences in all-cause mortality at 12 months. Further research is warranted to better understand the mechanisms underlying these associations.
- 1 January 2024
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 6 (1) , 4-16
Mitral Regurgitation Quantification, Management, and Guidelines: A 2024 Update
A comparison of the recommendations for the diagnosis and treatment of mitral regurgitation (MR), the second-most common valvular heart ailment in high-income countries, from the European Society of Cardiology/European Association for Cardio-Thoracic Surgery 2021 and American College of Cardiology/American Heart Association 2020 guidelines. We systematically reviewed and contrasted the guidelines on the diagnosis and treatment of MR to inform clinical judgment. A multimodal approach comprising a comprehensive history and physical examination, echocardiography, and, in some cases, cardiac magnetic resonance imaging, is the preferred method for diagnosis, treatment guidance, and follow-up in patients with valvular heart disease. Both guidelines agreed on the multidisciplinary approach of the heart team and the definition and grading of severe primary MR. There was substantial agreement on the thresholds for intervention, such as the onset of symptoms, left ventricular failure, and hypertrophy; however, there were differences among asymptomatic individuals with preserved ventricular function. While there was a consensus on the need for intervention in patients with severe secondary MR and those who continued to experience symptoms despite optimization of medical therapy, there was a disagreement regarding whether a transcatheter or surgical repair/replacement should be performed.
- 1 January 2024
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 6 (1) , 4-16
Mitral Regurgitation Quantification, Management, and Guidelines: A 2024 Update
A comparison of the recommendations for the diagnosis and treatment of mitral regurgitation (MR), the second-most common valvular heart ailment in high-income countries, from the European Society of Cardiology/European Association for Cardio-Thoracic Surgery 2021 and American College of Cardiology/American Heart Association 2020 guidelines. We systematically reviewed and contrasted the guidelines on the diagnosis and treatment of MR to inform clinical judgment. A multimodal approach comprising a comprehensive history and physical examination, echocardiography, and, in some cases, cardiac magnetic resonance imaging, is the preferred method for diagnosis, treatment guidance, and follow-up in patients with valvular heart disease. Both guidelines agreed on the multidisciplinary approach of the heart team and the definition and grading of severe primary MR. There was substantial agreement on the thresholds for intervention, such as the onset of symptoms, left ventricular failure, and hypertrophy; however, there were differences among asymptomatic individuals with preserved ventricular function. While there was a consensus on the need for intervention in patients with severe secondary MR and those who continued to experience symptoms despite optimization of medical therapy, there was a disagreement regarding whether a transcatheter or surgical repair/replacement should be performed.
- Open Access
- 1 July 2023
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 5 (2) , 80-86
In Hospital Mortality in Acute Heart Failure with Idiopathic Cardiomyopathy and Type II Diabetes
Background: Clinical characteristics and outcomes in patients with type 2 diabetes mellitus (T2DM) and acute heart failure (AHF) patients with idiopathic cardiomyopathy are not well known. Objective: The objective of our study is to determine all-cause mortality in patients with idiopathic cardiomyopathy presenting with AHF. Methods: We analyzed the data from 509 consecutive patients with idiopathic cardiomyopathy presenting with AHF to 47 hospitals in seven Middle Eastern countries (Saudi Arabia, Oman, Yemen, Kuwait, United Arab Emirates, Qatar, and Bahrain) between February and November 2012. All patients were stratified according to T2DM. The analyses were performed using the univariate and multivariate statistical techniques. Results: The mean age of the cohort was 52.0 ± 14.8 years. Of the 509 patients, 123 (24.2%) had T2DM and had a higher incidence of major stroke than the nondiabetic group (11.4% vs. 2.8%; P = 0.001). Diabetic patients were also more likely to be associated with hypertension than those without diabetes mellitus (78.9% vs. 21.8%; P < 0.001). Multivariate logistic regression demonstrated that those with cardiogenic shock (adjusted odds ratio [aOR], 59.3; 95% confidence interval [CI]: 20.1–207; P = 0.001) and noninvasive ventilation (NIV) (aOR: 4.19; 95% CI: 1.33–13.1; P = 0.013) were associated with higher odds of all-cause in-hospital mortality. However, age (aOR: 1.00; 95% CI: 0.96–1.03; P = 0.792), T2DM status (aOR: 0.43; 95% CI: 0.10–1.51; P = 0.207), and atrial fibrillation (aOR: 3.95; 95% CI: 0.82–17.2; P = 0.07) were not associated with higher odds of all-cause inhospital mortality. Conclusions: In AHF patients with idiopathic cardiomyopathy, T2DM was not associated with higher odds of all-cause inhospital mortality. Patients on NIV and cardiogenic shock were demonstrated as the independent predictors of increased inhospital mortality.
- 1 July 2023
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 5 (2) , 80-86
Open AccessIn Hospital Mortality in Acute Heart Failure with Idiopathic Cardiomyopathy and Type II Diabetes
Background: Clinical characteristics and outcomes in patients with type 2 diabetes mellitus (T2DM) and acute heart failure (AHF) patients with idiopathic cardiomyopathy are not well known. Objective: The objective of our study is to determine all-cause mortality in patients with idiopathic cardiomyopathy presenting with AHF. Methods: We analyzed the data from 509 consecutive patients with idiopathic cardiomyopathy presenting with AHF to 47 hospitals in seven Middle Eastern countries (Saudi Arabia, Oman, Yemen, Kuwait, United Arab Emirates, Qatar, and Bahrain) between February and November 2012. All patients were stratified according to T2DM. The analyses were performed using the univariate and multivariate statistical techniques. Results: The mean age of the cohort was 52.0 ± 14.8 years. Of the 509 patients, 123 (24.2%) had T2DM and had a higher incidence of major stroke than the nondiabetic group (11.4% vs. 2.8%; P = 0.001). Diabetic patients were also more likely to be associated with hypertension than those without diabetes mellitus (78.9% vs. 21.8%; P < 0.001). Multivariate logistic regression demonstrated that those with cardiogenic shock (adjusted odds ratio [aOR], 59.3; 95% confidence interval [CI]: 20.1–207; P = 0.001) and noninvasive ventilation (NIV) (aOR: 4.19; 95% CI: 1.33–13.1; P = 0.013) were associated with higher odds of all-cause in-hospital mortality. However, age (aOR: 1.00; 95% CI: 0.96–1.03; P = 0.792), T2DM status (aOR: 0.43; 95% CI: 0.10–1.51; P = 0.207), and atrial fibrillation (aOR: 3.95; 95% CI: 0.82–17.2; P = 0.07) were not associated with higher odds of all-cause inhospital mortality. Conclusions: In AHF patients with idiopathic cardiomyopathy, T2DM was not associated with higher odds of all-cause inhospital mortality. Patients on NIV and cardiogenic shock were demonstrated as the independent predictors of increased inhospital mortality.
- Open Access
- 1 July 2023
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 5 (2) , 69-74
Predictors of Early and Late Mortality after Transcatheter Aortic Valve Implantation: A Multicenter Retrospective Chinese Study
Background: Patients undergoing TAVR constitute a high-risk population given their comorbidities and out-of-hospital mortality rates remain high despite significant improvements in the overall procedural outcomes. Objectives: The objective of this study was to determine the early and late mortality rates following transfemoral transcatheter aortic valve replacement (TAVR) and identify the risk factors for poor outcomes. Methods: This study population examined patients extracted from 43 publicly funded hospitals in Hong Kong between 2010 and 2019. The study constitutes retrospective analysis of mortality outcomes for severe aortic stenosis patients undergoing TAVR. The primary end points include out-of-hospital 30-day, 1-year, 1–2-year, and 2–5-year mortality rates. Results: A total of 448 patients underwent TAVR and were included into the study. The rates of mortality following TAVR were 1.7%, 3.3%, 1.3%, and 0.22% at 30 days, 1, 1–2, and 2–5 years, respectively. Age and chronic renal failure (CRF) were concluded to be associated with postprocedural mortality. Further analysis of the baseline echocardiographic parameters revealed a higher prevalence of right atrial enlargement (RAE) and tricuspid and pulmonary regurgitation in the deceased subgroup. Conclusion: We report the 30-day, 1-, 1–2-, and 2–5-year all-cause mortality for TAVR of 1.7%, 3.3%, 1.3%, and 0.22% at 30 days. Factors associated with a higher prevalence of mortality include age, CRF, RAE, and tricuspid and pulmonary regurgitation.
- 1 July 2023
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 5 (2) , 69-74
Open AccessPredictors of Early and Late Mortality after Transcatheter Aortic Valve Implantation: A Multicenter Retrospective Chinese Study
Background: Patients undergoing TAVR constitute a high-risk population given their comorbidities and out-of-hospital mortality rates remain high despite significant improvements in the overall procedural outcomes. Objectives: The objective of this study was to determine the early and late mortality rates following transfemoral transcatheter aortic valve replacement (TAVR) and identify the risk factors for poor outcomes. Methods: This study population examined patients extracted from 43 publicly funded hospitals in Hong Kong between 2010 and 2019. The study constitutes retrospective analysis of mortality outcomes for severe aortic stenosis patients undergoing TAVR. The primary end points include out-of-hospital 30-day, 1-year, 1–2-year, and 2–5-year mortality rates. Results: A total of 448 patients underwent TAVR and were included into the study. The rates of mortality following TAVR were 1.7%, 3.3%, 1.3%, and 0.22% at 30 days, 1, 1–2, and 2–5 years, respectively. Age and chronic renal failure (CRF) were concluded to be associated with postprocedural mortality. Further analysis of the baseline echocardiographic parameters revealed a higher prevalence of right atrial enlargement (RAE) and tricuspid and pulmonary regurgitation in the deceased subgroup. Conclusion: We report the 30-day, 1-, 1–2-, and 2–5-year all-cause mortality for TAVR of 1.7%, 3.3%, 1.3%, and 0.22% at 30 days. Factors associated with a higher prevalence of mortality include age, CRF, RAE, and tricuspid and pulmonary regurgitation.
- Open Access
- 11 April 2023
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 5 (2) , 91-94
Uncommon Association between Crohn’s Disease and Takayasu Arteritis with Ostial Left Main Disease
Crohn’s disease (CD) and Takayasu arteritis (TA) are distinct clinical entities. The likelihood of both diseases coexisting is low, and although CD co-occurs with all types of vasculitis, TA is the most common subtype. Herein, we report the case of a 31-year-old female who was diagnosed with TA following an initial diagnosis of CD. Coronary angiography revealed subtotal ostial left main stenosis and chronic total occlusion of the right coronary artery with collaterals from the left system. An urgent coronary artery bypass graft was planned.
- 11 April 2023
- Published by Medknow in Annals of Clinical Cardiology
- Vol. 5 (2) , 91-94
Open AccessUncommon Association between Crohn’s Disease and Takayasu Arteritis with Ostial Left Main Disease
Crohn’s disease (CD) and Takayasu arteritis (TA) are distinct clinical entities. The likelihood of both diseases coexisting is low, and although CD co-occurs with all types of vasculitis, TA is the most common subtype. Herein, we report the case of a 31-year-old female who was diagnosed with TA following an initial diagnosis of CD. Coronary angiography revealed subtotal ostial left main stenosis and chronic total occlusion of the right coronary artery with collaterals from the left system. An urgent coronary artery bypass graft was planned.
- Open Access
- 7 June 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (10) , 5880-5885
In‐hospital mortality in SARS‐CoV‐2 stratified by serum 25‐hydroxy‐vitamin D levels: A retrospective study
This study is done to estimаte in‐hоsрitаl mоrtаlity in раtients with severe асute resрirаtоry syndrоme соrоnаvirus 2 (SАRS‐СоV‐2) strаtified by Vitamin‐D (Vit‐D) levels. Раtients were strаtified ассоrding tо by serum 25‐hydroxy‐vitamin D (25(OH)Vit‐D) levels intо twо grоuрs, that is, 25(OH)Vit‐D less thаn 40 nmol/L аnd 25(OH)Vit‐D greаter thаn 40 nmol/L. А tоtаl оf 231 раtients were inсluded. Оf these, 120 (50.2%) оf the раtients hаd 25(OH)Vit‐D levels greаter thаn 40 nmol/L. The meаn аge wаs 49 ± 17 yeаrs, аnd 67% оf the раtients were mаles. The mediаn length оf оverаll hоsрitаl stаy wаs 18 [6; 53] dаys. The remаining 119 (49.8%) раtients hаd а 25(OH)Vit‐D less thаn 40 nmol/L. Vitamin D levels were seen as deficient in 63% of patients, insufficient in 25% and normal in 12%. Оverаll mоrtаlity wаs 17 раtients (7.1%) but statistically not signifiсаnt among the grоuрs (p = 0.986). The Kарlаn–Meier survivаl аnаlysis shоwed no significance based on an alpha of 0.05, LL = 0.36, df = 1, p = 0.548, indicating Vitamin_D_Levels was not able to adequately predict the hazard of Mortality. In this study, serum 25(OH)Vit‐D levels were found have no significance in terms of predicting the in‐hоsрitаl mortality in раtients with SАRS‐СоV‐2.
- 7 June 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (10) , 5880-5885
Open AccessIn‐hospital mortality in SARS‐CoV‐2 stratified by serum 25‐hydroxy‐vitamin D levels: A retrospective study
This study is done to estimаte in‐hоsрitаl mоrtаlity in раtients with severe асute resрirаtоry syndrоme соrоnаvirus 2 (SАRS‐СоV‐2) strаtified by Vitamin‐D (Vit‐D) levels. Раtients were strаtified ассоrding tо by serum 25‐hydroxy‐vitamin D (25(OH)Vit‐D) levels intо twо grоuрs, that is, 25(OH)Vit‐D less thаn 40 nmol/L аnd 25(OH)Vit‐D greаter thаn 40 nmol/L. А tоtаl оf 231 раtients were inсluded. Оf these, 120 (50.2%) оf the раtients hаd 25(OH)Vit‐D levels greаter thаn 40 nmol/L. The meаn аge wаs 49 ± 17 yeаrs, аnd 67% оf the раtients were mаles. The mediаn length оf оverаll hоsрitаl stаy wаs 18 [6; 53] dаys. The remаining 119 (49.8%) раtients hаd а 25(OH)Vit‐D less thаn 40 nmol/L. Vitamin D levels were seen as deficient in 63% of patients, insufficient in 25% and normal in 12%. Оverаll mоrtаlity wаs 17 раtients (7.1%) but statistically not signifiсаnt among the grоuрs (p = 0.986). The Kарlаn–Meier survivаl аnаlysis shоwed no significance based on an alpha of 0.05, LL = 0.36, df = 1, p = 0.548, indicating Vitamin_D_Levels was not able to adequately predict the hazard of Mortality. In this study, serum 25(OH)Vit‐D levels were found have no significance in terms of predicting the in‐hоsрitаl mortality in раtients with SАRS‐СоV‐2.